Peptides Used Under Medical Supervision as Part of Root Cause Functional Medicine
The speaker notes that peptides and LDN are used under medical supervision within their functional medicine program, implying these are not over-the-counter or self-administered protocols. This is the only safety-adjacent statement made regarding peptide use in the video — no contraindications, side effects, or drug interactions are discussed. The speaker positions medical oversight as a key differentiator of their clinic's approach versus self-directed protocols.
Peptides Referenced as Advanced Clinical Tools Most Specialists Are Unaware Of
The speaker frames peptides (alongside LDN) as advanced tools that 'most specialists have never heard of,' positioning them as a distinguishing feature of functional medicine practice versus conventional care. The cost of LDN ($30–$90/month from compounding pharmacies) is mentioned as context for accessibility, though no peptide pricing is given. This framing serves as both a clinical observation and a marketing claim. No safety warnings or contraindications are discussed for the peptides.
Peptides Positioned as Complementary to LDN — Each Addressing Distinct Mechanisms
The speaker explicitly distinguishes the mechanisms of peptides from those of LDN, stating that 'no peptides can do what LDN does' in targeting central nervous system inflammation via microglial pathways. This implies the peptides in the stack are viewed as complementary rather than interchangeable with LDN, each filling a different mechanistic role (gut lining, NF-κB, tight junctions vs. CNS immune modulation). No dosages are specified. This framing positions the combined protocol as superior to any single agent.
Peptide Stack Combined with LDN and GLP-1 as a Multi-Modal Anti-Inflammatory Protocol
The speaker describes layering the peptide stack (BPC-157, KPV, Larazotide) on top of Low Dose Naltrexone (LDN) and micro-dosed GLP-1 medications as a potent combined anti-inflammatory protocol. The GLP-1 micro-dosing is explicitly noted as being used for anti-inflammatory purposes rather than weight loss or diabetes management. No specific peptide dosages are given, though GLP-1 escalation from 2.5 to 10 mg over 6 months is mentioned in a patient case. This is presented as the clinic's advanced multi-system approach.
Peptides Described as Turning Off Inflammation at a Genetic Level
The speaker makes a broad claim early in the video that peptides can 'turn off inflammation at a genetic level,' framing this as a distinguishing feature of the clinical tools used in their practice. This claim is most directly supported by the subsequent description of KPV's NF-κB inhibition mechanism, which operates at the level of gene transcription. No specific dosages or study citations are provided for this overarching claim. It is presented as a key differentiator from standard dietary interventions.
Peptide Stack (BPC-157 + KPV + Larazotide) for Gut and Systemic Inflammation
The speaker describes a three-peptide clinical stack combining BPC-157, KPV, and Larazotide as a coordinated approach to gut and systemic inflammation. Each peptide is said to address a distinct mechanism: BPC-157 heals the gut lining and boosts antioxidants, KPV blocks NF-κB inflammatory gene activation, and Larazotide repairs tight junctions and the zonulin pathway. No individual or combined dosages are specified. This stack is presented as a standard clinical protocol in the speaker's functional medicine clinic.
BPC-157 for Gut Lining Healing and Antioxidant Upregulation
BPC-157 (referred to as 'BBC' in the transcript, likely a verbal shorthand or transcription error for BPC-157) is described as healing the gut lining and upregulating the body's antioxidant system, which the speaker claims ultimately reduces inflammation. No specific dosage is mentioned. This is presented as part of a clinical peptide stack used in the speaker's functional medicine practice.
Safety Warning: Pharmaceutical-Grade Peptides Required (503A Pharmacy)
The speaker issues a sourcing warning, stating that research-grade peptides are not equivalent to pharmaceutical-grade peptides and advising viewers to obtain peptides exclusively from a 503A compounding pharmacy. This is framed as a critical safety or quality rule. No specific data on contaminant risks or purity differences between grades is provided.
Oral BPC-157 Superior to Injectable for Gut Healing
The speaker asserts that oral administration of BPC-157 is more effective than injection specifically for gut healing, because it delivers the peptide directly to the gut lining. This represents a route-of-administration recommendation specific to gastrointestinal indications. No pharmacological or clinical evidence is cited to support this claim.
Systemic Biodistribution: Injection Site Independence
The speaker claims that both BPC-157 and TB-500 work systemically, meaning injection does not need to occur directly at the injury site for the peptides to be effective. Despite this, the speaker acknowledges that injecting at the injury site is common practice, including in his own use. No pharmacokinetic studies are cited.
The Wolverine Stack: BPC-157 + TB-500 Combination Protocol
The speaker recommends combining BPC-157 and TB-500 — referred to as the 'Wolverine stack' — for nagging injuries, slow recovery, and gut issues. The standard protocol is 500 micrograms of each peptide daily for a 3-month cycle. This is presented as a clinical recommendation without citation of controlled studies.
BPC-157 Mechanism of Action: Tissue Repair and Inflammation
BPC-157 is described as stimulating the body's natural repair signals to accelerate tissue healing and reduce inflammation. It is also noted to repair gut lining. No clinical trials or studies are cited; the claims are presented as clinical assertions by the speaker.
GLP-1 Medications Do Not Repair Gut Lining Despite Systemic Anti-Inflammatory Effects
Dr. Jones asserts that while GLP-1 receptor agonists reduce inflammation systemically, they do not specifically repair a compromised gut barrier. He claims that if gut barrier integrity is not restored, inflammation will continue to recycle regardless of GLP-1 medication use — establishing the rationale for adjunct peptide therapy with KPV and BPC-157.
Gut Inflammation Reduction Improves Insulin Resistance and GLP-1 Efficacy
Dr. Jones describes a compounding downstream effect: when gut inflammation is reduced (via KPV and BPC-157), insulin resistance improves, and when insulin resistance improves, the GLP-1 medication becomes more effective. He frames persistent gut inflammation as a 'bottleneck' limiting GLP-1 drug performance.
Route of Administration Determines BPC-157 Therapeutic Target
The overarching claim is that oral and injectable BPC-157 are not interchangeable. The delivery method dictates the primary therapeutic target: oral for gut problems, injectable for musculoskeletal injuries. The speaker frames this as a protocol-selection principle for his clinic patients.
Oral BPC-157 + KPV Stack for Gut Inflammation
The speaker recommends combining oral BPC-157 with KPV (alpha-MSH fragment) as one of the most effective inflammation reduction protocols seen in his clinic. The combination is said to improve the gut barrier and produce downstream anti-inflammatory effects throughout the entire body. No dosages or cycling details were provided.
Oral BPC-157 Has Minimal Systemic Bioavailability
The speaker warns that taking oral BPC-157 for a peripheral musculoskeletal injury (e.g., knee) is potentially wasteful because oral bioavailability for systemic tissues is minimal. This is framed as a key reason the two routes of administration are not interchangeable.
Oral BPC-157 for Gut Healing and GI Conditions
Oral BPC-157 is recommended for gut-specific conditions including leaky gut, GERD, IBS, bloating, and chronic gut inflammation. The rationale is that oral administration concentrates the peptide where it is naturally produced — the stomach and intestines. Oral BPC-157 also improves the gut barrier and has downstream anti-inflammatory effects throughout the body. No dosages were specified.
Injectable BPC-157 for Musculoskeletal Injury Healing
Injectable BPC-157 is recommended for systemic and musculoskeletal healing, specifically for rotator cuffs, ACL injuries, Achilles injuries, joint pain, and chronic injuries. The speaker advises injecting near the site of injury when possible, or subcutaneously into fat tissue as an alternative. No specific dosages were mentioned.
Warning against simultaneous multi-peptide stacking
Dr. Jones warns that taking five or more peptides concurrently — a common biohacker practice — leads to wasted money and minimal results. This is framed as a safety/efficacy warning based on his clinical observations, though no adverse effects are specified beyond lack of efficacy.
Phased peptide protocol: Foundation → Healing → Optimization → Anti-Aging
Dr. Jones's clinic uses a sequential phasing approach rather than simultaneous stacking: (1) Foundation, (2) Healing, (3) Optimization, (4) Anti-aging. He warns that skipping phases wastes money and rushing the stack yields no results. No specific peptide-to-phase assignments or dosages are provided in this transcript.
Peptide sequencing order matters more than the stack composition
Dr. Jones argues that the order in which peptides are introduced matters more than which peptides are combined. He observes that people taking five peptides simultaneously (BPC-157, TB-500, GH secretagogues, fat loss peptides, anti-aging compounds) often get poor results. No dosages mentioned.
Integrated autoimmune protocol: root cause + peptides + medical oversight
Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.
BPC-157, KPV, and Larazotide for gut repair and systemic inflammation in autoimmune patients
As part of a layered functional medicine protocol for autoimmune conditions, Dr. Jones recommends peptides BPC-157 ('BPC57' as spoken), KPV, and Larazotide specifically for gut repair and reducing systemic inflammation. These are positioned as advanced tools used after foundational interventions (gut health, anti-inflammatory diet, nutrient repletion) are in place. No specific dosages are provided.
Warning: Peptides mask autoimmune root cause in lupus
Dr. Jones warns that relying on peptide therapies without addressing the underlying autoimmune drivers of lupus leads to expensive, chronic dependency on repeated peptide cycles. He argues that addressing root causes (gut health, inflammation, nutrient deficiencies, dietary triggers, nervous system) reduces the need for ongoing peptide use, making treatment more sustainable.
Lupus patients using BPC-157 and TB-500 as symptom management
Dr. Jones observes that many lupus patients are using peptide therapies like BPC-157 and TB-500 (referred to collectively with 'the Wolverine' stack) to manage joint pain and inflammation symptoms. He states he'd prefer patients use these over harmful biologics or corticosteroids, but cautions that they are still masking the underlying autoimmune problem rather than addressing root cause.
Sourcing Warning: Pharmacy-Grade vs. Research Chemical Peptides
Dr. Jones warns that peptide sourcing is more important than the peptide selection itself. He states that research-grade chemicals lack consistency and recommends only pharmacy-grade peptides. This is positioned as a safety and efficacy concern — implying that research chemicals may be underdosed, contaminated, or inconsistent in formulation.
BPC-157 Mechanism: Angiogenesis at Injury Site
Dr. Jones attributes the mechanism of building new blood vessels directly into the injury site to one of the two peptides in the stack. Based on established literature, this angiogenic property aligns with BPC-157. No citations or study references are provided in the video.
The Wolverine Stack: BPC-157 + TB-500 Combination for Injury Repair
Dr. Jones describes a peptide stack he calls 'The Wolverine Stack' combining BPC-157 and TB-500 for injury healing. He claims the two peptides work synergistically — one promotes angiogenesis (new blood vessel formation) into the injury site, while the other recruits repair cells to the area. No specific dosages or injection protocols are provided.
BPC-157 + TB-500 blend: twice-weekly dosing is also effective
Twice-weekly dosing of the BPC-157/TB-500 blend can also work because the TB-500 component maintains effectiveness through its intracellular mechanism regardless of frequency. However, this is suboptimal for the BPC-157 component. The speaker notes either strategy works and comes down to personal preference.
BPC-157 + TB-500 blend: daily dosing is the optimal protocol
When using a pre-made BPC-157/TB-500 blend, daily dosing is recommended. Daily administration does not reduce TB-500 effectiveness (since total weekly exposure remains comparable) while ensuring maximum BPC-157 benefit due to its presence-dependent mechanism. The blend makes daily dosing the simpler and more effective strategy.
BPC-157 requires daily (or twice daily) dosing for maximum effectiveness
Due to its short half-life and presence-dependent mechanism, BPC-157 should be dosed daily or even twice daily for maximum effectiveness. Dosing only a couple times per week would leave the body without active peptide for extended periods, reducing therapeutic benefit.
BPC-157 mechanism: angiogenesis and increased blood flow to damaged tissue
BPC-157 drives the creation of new blood vessels (angiogenesis) and increases blood flow to damaged tissue. This is presented as its primary mechanism of action for tissue repair. The effect is presence-dependent, requiring the peptide to be in the system to exert its action.
BPC-157 has a very short plasma half-life (~2 hours)
BPC-157 clears from the bloodstream within approximately 2 hours. Its therapeutic effect depends on the peptide being actively present in plasma, meaning its benefits are tied to continuous exposure rather than residual intracellular activity.
BPC-157 and TB-500 Angiogenesis Is Not Cancer-Promoting
Dr. Bachmeyer briefly addresses concerns about BPC-157 and TB-500 causing cancer via angiogenesis. He states that the angiogenesis promoted by these peptides is controlled, well-regulated biological growth — not the erratic, uncontrolled growth that cancer requires. He urges listeners to 'stop and smell the biology.'
Safety claim: cannot overdose on KPV, BPC-157, or TB-500
Dr. Bachmeyer claims that you cannot overdose and die from KPV, BPC-157, or TB-500, contrasting these with statins, NSAIDs, and prednisone which can cause fatal overdose. He argues that since the body naturally produces the parent compounds (e.g., alpha-MSH for KPV), they are inherently safer than synthetic pharmaceuticals.
BPC-157, TB-500, and GHK-Cu blend criticism — incompatible half-lives
Dr. Bachmeyer argues blends of BPC-157, TB-500, and GHK-Cu are ineffective for two reasons: (1) they get corrupted inside the vial, and (2) incompatible half-lives make co-administration illogical. TB-500 has a ~5-day half-life (dosed near-weekly) while BPC-157 has a ~1-day half-life (dosed daily). You either micro-dose TB-500 (which he says just 'tickles receptors' and doesn't work) or skip days of BPC-157. He also states GHK-Cu 'demolishes' in blends (copper interaction).
IM Route Preferred for Faster Peptide Absorption in Acute Viral Cases
Speaker specifically chose intramuscular (IM) administration for Thymosin Alpha-1, LL-37, and BPC-157 rather than subcutaneous, stating the rationale was faster absorption needed in active viral suppression cases. KPV was the exception, administered subcutaneously.
Complete HSV Peptide + Supplement Stack Protocol
Complete protocol combining immune retraining (Thymosin Alpha-1 IM 2x/week, LL-37 IM daily), direct antivirals (Monolaurin 3g/day, L-Lysine 3g/day in 3 divided doses), anti-inflammatory control (KPV 300-400mcg subQ daily), nerve repair (BPC-157 IM daily), and nutritional restoration (Magnesium glycinate 400mg, Zinc 30mg, Vitamin D3 5000IU + K2 200mcg, Selenium 200mcg, NAC 600mg 2x/day). Patient achieved zero outbreaks in 90 days after 8 years of monthly outbreaks.